Purpose To estimate the impact of delayed care during the coronavirus disease 2019 (COVID-19) pandemic on the outcomes of patients with neovascular age-related macular degeneration (AMD). Methods Consecutive patients with diagnosis of neovascular AMD were consecutively enrolled between March 9, 2020, and June 12, 2020, (during and immediately after the Italian COVID-19 quarantine). During the inclusion (or pandemic) visit (V 0 ), patients received a complete ophthalmologic evaluation, including optical coherence tomography (OCT). Best-corrected visual acuity (BCVA) and OCT findings from the two preceding visits (V −1 and V −2 ) were compared with data at V 0 . Results One-hundred patients (112 eyes) were enrolled in this study. The time interval between following visits was 110.7 ± 37.5 days within V 0 and V −1 and 80.8 ± 39.7 days within V −1 and V −2 , respectively ( P  < 0.0001). BCVA was statistically worse at the V 0 visit as compared with the immediately preceding (V −1 ) visit (0.50 ± 0.43 LogMAR and 0.45 ± 0.38 LogMAR at the V 0 and V −1 visits, respectively; P  = 0.046). On structural OCT, 91 out of 112 (81.2%) neovascular AMD eyes displayed the evidence of exudative disease activity at the V 0 visit, while 77 (68.7%) eyes exhibited signs of exudation at the V −1 visit ( P  = 0.022). No differences in terms of BCVA and OCT findings were detected between the V −1 and V −2 visits. In multiple regression analysis, the difference in BCVA between V 0 and V −1 visits was significantly associated with the interval time within these two visits ( P  = 0.026). Conclusion The COVID-19 pandemic-related postponement in patient care proved to be significantly associated with worse short-term outcomes in these patients.